A patient-specific human iPSC model of calmodulinopathy identifies calcium channel blockade as a potential therapy mechanism

Calmodulinopathy is a life-threatening cardiac arrhythmia syndrome resulting from a heterozygous mutation in any of the three calmodulin (CaM) genes CALM1 , CALM2 , or CALM3 . Despite treatment with typical antiarrhythmic drug therapies, more than half of individuals with a pathogenic CALM variant experience major arrhythmic events such as aborted cardiac arrest or sudden cardiac death. Currently we have limited knowledge linking different CALM genetic variants to cellular phenotypes and the pharmacogenomic relationship between variant and potential drug therapy. To address this, we generated hiPSC-CMs from five CaM - LQTS patients harboring different heterozygous CALM variants and assessed in vitro function using a combination of assays for Ca 2+ dynamics, impedance, and extracellular and transmembrane voltage. We identified lower beat rate and prolonged Ca 2+ transients as common features of calmodulinopathic hiPSC-CMs. Microelectrode array and patch clamp recording of action potentials demonstrated that hiPSC-CMs with variants in EF-hand III have greater pulse width, longer action potential duration, and increased maximum upstroke velocity that were not observed in the EF-hand IV variant hiPSC-CMs. With an established in vitro phenotype detectable in multiparameter high-throughput assays, we tested a selection of four clinically relevant drugs for use as potential calmodulinopathy therapies. We observed that calcium channel blockers verapamil and diltiazem alleviated the CaM-LQTS phenotype in hiPSC-CMs with both the CALM2 D96G and D96V variants albeit at supratherapeutic doses. Our findings support clinical investigation of calcium channel blockade as a potential mechanistic target for calmodulinopathy and that hiPSC-CMs can facilitate the study calmodulinopathy therapies in a patient- and variant-specific manner.

Authors

Institutions

Publication Details

Journal
Stem Cell Research & Therapy
Published
2026-11-16
DOI
https://doi.org/10.1186/s13287-026-05403-9
Primary Topic
Cardiac electrophysiology and arrhythmias
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A patient-specific human iPSC model of calmodulinopathy identifies calcium channel blockade as a potential therapy mechanism

Carly J. Weddle, Hananeh Fonoudi, Malorie Blancard, Mariam Jouni et al.
Stem Cell Research & Therapy
Cardiac electrophysiology and arrhythmias
article

A patient-specific human iPSC model of calmodulinopathy identifies calcium channel blockade as a potential therapy mechanism

Carly J. Weddle, Hananeh Fonoudi, Malorie Blancard, Mariam Jouni, Paul W. Burridge, Justina Hathi, Gregory Webster, K. Ashley Fetterman, Alfred L. George
article en

Abstract

Calmodulinopathy is a life-threatening cardiac arrhythmia syndrome resulting from a heterozygous mutation in any of the three calmodulin (CaM) genes CALM1 , CALM2 , or CALM3 . Despite treatment with typical antiarrhythmic drug therapies, more than half of individuals with a pathogenic CALM variant experience major arrhythmic events such as aborted cardiac arrest or sudden cardiac death. Currently we have limited knowledge linking different CALM genetic variants to cellular phenotypes and the pharmacogenomic relationship between variant and potential drug therapy. To address this, we generated hiPSC-CMs from five CaM - LQTS patients harboring different heterozygous CALM variants and assessed in vitro function using a combination of assays for Ca 2+ dynamics, impedance, and extracellular and transmembrane voltage. We identified lower beat rate and prolonged Ca 2+ transients as common features of calmodulinopathic hiPSC-CMs. Microelectrode array and patch clamp recording of action potentials demonstrated that hiPSC-CMs with variants in EF-hand III have greater pulse width, longer action potential duration, and increased maximum upstroke velocity that were not observed in the EF-hand IV variant hiPSC-CMs. With an established in vitro phenotype detectable in multiparameter high-throughput assays, we tested a selection of four clinically relevant drugs for use as potential calmodulinopathy therapies. We observed that calcium channel blockers verapamil and diltiazem alleviated the CaM-LQTS phenotype in hiPSC-CMs with both the CALM2 D96G and D96V variants albeit at supratherapeutic doses. Our findings support clinical investigation of calcium channel blockade as a potential mechanistic target for calmodulinopathy and that hiPSC-CMs can facilitate the study calmodulinopathy therapies in a patient- and variant-specific manner.

Stem Cell Research & Therapy
Northwestern University (US), Lurie Children's Hospital (US), Lurie Children's Hospital (US)
Good health and well-being
Cardiac electrophysiology and arrhythmias
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon